Agency / Source: IPSEN Group

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Ipsen Adds Another Program into its Pre-clinical R&D Oncology Pipeline through An Exclusive Worldwide Collaboration with Accent Therapeutics - Ipsen adds another program into its pre-clinical R&D Oncology pipeline through an exclusive worldwide collaboration with Accent Therapeutics, targeting the RNA modifying protein, METTL3 - Accenttx.com / Ipsen.com
Ipsen Adds Another Program into its Pre-clinical R&D Oncology Pipeline through An Exclusive Worldwide Collaboration with Accent Therapeutics

 

PRZOOM - /newswire/ - Paris, Ile-de-France, France, 2021/10/18 - Ipsen adds another program into its pre-clinical R&D Oncology pipeline through an exclusive worldwide collaboration with Accent Therapeutics, targeting the RNA modifying protein, METTL3 - Accenttx.com / Ipsen.com. Euronext: IPN; ADR: IPSEY

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

• Ipsen obtains an exclusive license to develop, manufacture and commercialize;
• a pre-clinical stage METTL3-inhibitor program;
• Building on recent announcements, this collaboration with Accent Therapeutics reinforces Ipsen’s expansion into hematological malignancies, with a focus on acute myeloid leukemia.

Ipsen and Accent Therapeutics (Accent) have signed an exclusive worldwide-collaboration agreement to research, develop, manufacture, and commercialize Accent’s pre-clinical stage METTL3 program.

Acute myeloid leukemia (AML) is a difficult to treat cancer of the blood and bone marrow, accounting for a third of all new cases of leukemia in the US each year.1 Globally, the incidence of AML has been increasing year on year across the last 20 years.2 RNA modifying proteins (RMPs) are an emerging target class that control multiple aspects of RNA biology and represent a new approach for the potential treatment of various cancers. METTL3 is an RMP that has been validated pre-clinically as a novel therapeutic target for AML.1,3 This collaboration combines Accent’s expertise in RMP-targeting therapeutics with Ipsen’s capabilities and proven track record in Oncology medicine development and commercialization.

Christelle Huguet, Senior Vice President, Head of Research, External Innovation and Early Development, Ipsen, said “Oncology is a key focus area for Ipsen as we grow our pipeline. We are delighted to partner with Accent to progress the METTL3 program as we continue our expansion into hematologic oncology. Our teams are steadfast in our commitment to areas of high unmet medical need including rare cancers, so this collaboration is strongly aligned with Ipsen’s mission and strategy for growth.”

Shakti Narayan, Chief Executive Officer of Accent Therapeutics said “This collaboration blends Ipsen’s commitment to developing and commercializing transformative oncology medicines with Accent’s leading expertise in the field of RNA modification. As we focus on developing our rich pipeline of novel RMP-targeted therapies, we are pleased to entrust our METTL3 program to the innovative team at Ipsen to bring this novel investigational therapy to patients in need.”

Under the agreement, Ipsen will pay up to $446m, comprising upfront payment as well as pre-clinical, clinical, regulatory, and sales-based milestone payments, plus tiered sales royalties ranging from mid-single digits to low-double digits.

METTL3 program

One of the most prevalent modifications within mRNA is the methylation of the adenine base at the N6 position, resulting in N6-methyladenosine (m6A). This modification is catalyzed by the methyltransferase enzyme complex METTL3/METTL14. m6A is involved in several aspects of mRNA stability and turnover, controls translation of oncogenes that confer growth advantage and migratory behavior and has emerged as a key mRNA modification implicated in hematological cancers. Knockout of METTL3 and/or METTL14 promotes AML differentiation and apoptosis and has been shown to be important for both in vitro and in vivo growth for AML. Accent Therapeutic’s novel investigational small molecule inhibitors of METTL3 seek to treat specific sub-types of AML with high unmet medical need.

About Ipsen

Ipsen (ipsen.com) is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience; it also has a well-established Consumer Healthcare business. With Total Sales of over €2.5bn in FY 2020, Ipsen sells more than 20 medicines in over 115 countries, with a direct commercial presence in more than 30 countries. The Company’s research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen has c.5,700 colleagues worldwide.

About Accent Therapeutics

Accent Therapeutics (accenttx.com) is a biopharmaceutical company developing oncology-focused, small molecule therapies in the emerging field of RNA modification. This field of biology encompasses post-transcriptional chemical modifications of RNA that provide cells with a unique mechanism for regulating proteins critical for cellular growth and differentiation. By targeting cancer-linked RNA-modifying proteins (RMPs) with precision therapies, the company is translating extraordinary science into life-changing therapies for patients.

1. American Cancer Society. Key statistics for Acute Myeloid Leukemia. cancer.org/cancer/acute-myeloid-leukemia/about/key-statistics.html
2. Yin Dong, Oumin Shi, Quanxiang Zeng, Xiaoquin Lu, Wei Wang, Yong Li, Qi Wang, Yong Li and Qi Wang, Leukemia incidence trends at the global, regional, and national level between 1990 and 2017. Experimental Hematology & Oncology 9, Article number 14. 2020
3. Shane M Buker, Zachary A Gurard-Levin, Benjamin D Wheeler, Michael D Scholle, April W Case, Jeffrey L Hirsch, Scott Ribich, Robert A Copeland, P Ann Boriack-Sjodin. A Mass Spectrometric Assay of METTL3/METTL14 4. Methyltransferase Activity. SLAS Discov. 2020 Apr;25(4):361-371. Epub 2019 Oct 4.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: IPSEN Group

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Ipsen Adds Another Program into its Pre-clinical R&D Oncology Pipeline through An Exclusive Worldwide Collaboration with Accent Therapeutics

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Accent Therapeutics | Ipsen
Contact: Jess Smith - Ipsen.com 
+44(0)75 5726 7634
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any IPSEN Group securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From IPSEN Group / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Press Releases:

U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab & hyaluronidase-nvhy) Injection
NEC Announces Interim Results from Phase 1 Clinical Trial of NECVAX-NEO1
SCHOTT Pharma Unveils Innovative Nest Design for Ready-to-use Cartridges
Ipsen and Biomunex Announce Exclusive Global Licensing Agreement for First-in-class MAIT Cell Engager in Immuno-oncology
Bushu Pharma Applauded by Frost & Sullivan for Offering Customer Value in APAC CDMO Industry through Consistent Quality Assurance, On-time Delivery
Bylvay® (odevixibat) Data Shows Sustained Improvement in Severe Itch and Serum Bile Acid Levels in Patients with PFIC and ALGS
Genome BC, STEMCELL Technologies and UBC Partner to Accelerate the Ability to Develop Stem Cells
PathogenDx Applauded by Frost & Sullivan for Enabling Early and Precise UTI Diagnosis with its Microarray Detection Platform
BASF Partners with Acies Bio to Drive Sustainable Production of Personal and Home Care Ingredients
Ipsen’s Kayfanda® (odevixibat) Approved in European Union for Cholestatic Pruritus in Alagille Syndrome, A Rare Liver Disease

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com

Visit  RightITnow, Inc.







 
  ©2005-2025 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today